ArticleBMC veterinary research2014
Corynebacterium pseudotuberculosis cp09 mutant and cp40 recombinant protein partially protect mice against caseous lymphadenitis.
Article in BMC veterinary research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 42 citations in OpenAlex.
- Development of a bacterin-toxoid vaccine using a Korean isolate for protection against caseous lymphadenitis in goats.Veterinary research · 2026Article
- Oral fluid as a material for serological diagnostics of caseous lymphadenitis in goats.Scientific reports · 2025Article
- Immunization of mice and goats with Corynebacterium pseudotuberculosis-derived rPTS, rRBN and rCP40 recombinant proteins.World journal of microbiology & biotechnology · 2025Article
- Immunomodulating Enzymes fromMicroorganisms · 2024Review
- Bioinformatic Approach of B and T Cell Epitopes of PLD and CP40 Proteins ofInternational journal of molecular sciences · 2023Article
- Article
- Multi-Omics ofProteomes · 2022Article
- Vaccines for caseous lymphadenitis: up-to-date and forward-looking strategies.Applied microbiology and biotechnology · 2021Review
- Article
- A panel of recombinant proteins for the serodiagnosis of caseous lymphadenitis in goats and sheep.Microbial biotechnology · 2019Article
- Immune-Informatic Analysis and Design of Peptide Vaccine From Multi-epitopes AgainstBioinformatics and biology insights · 2018Article
- Chemical composition, immunostimulatory, cytotoxic and antiparasitic activities of the essential oil from Brazilian red propolis.PloS one · 2018Article
- A shift in the virulence potential of Corynebacterium pseudotuberculosis biovar ovis after passage in a murine host demonstrated through comparative proteomics.BMC microbiology · 2017Article
- Insight of GenusFrontiers in microbiology · 2017Review
- CP40 from Corynebacterium pseudotuberculosis is an endo-β-N-acetylglucosaminidase.BMC microbiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCaseous lymphadenitis (CLA) is an infectious disease that affects small ruminants and is caused by Corynebacterium pseudotuberculosis. This disease is responsible for high economic losses due to condemnation and trim of infected carcasses, decreased leather and wool yield, loss of sales of breeding stock and deaths from internal involvement. Treatment is costly and ineffective; the most cost-effective strategy is timely immunisation. Various vaccine strategies have been tested, and recombinant vaccines are a promising alternative. Thus, in this study, different vaccine formulations using a recombinant protein (rCP40) and the CP09 live recombinant strain were evaluated. Five groups of 10 mice each were immunised with saline (G1), rCP40 (G2), CP09 (G3), a combination of CP09 and rCP40 (G4) and a heterologous prime-boost strategy (G5). Mice received two immunisations within 15 days. On day 30 after primary immunisation, all groups were challenged with a C. pseudotuberculosis virulent strain. Mice were monitored and mortality was recorded for 30 days after challenge.
resultsThe G2, G4 and G5 groups showed high levels of IgG1 and IgG2a; G2 presented significant IgG2a production after virulent challenge in the absence of IgG1 and IgG3 induction. Thirty days after challenge, the mice survival rates were 20 (G1), 90 (G2), 50 (G3), 70 (G4) and 60% (G5).
conclusionsrCP40 is a promising target in the development of vaccines against caseous lymphadenitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.